Abstracts tagged "acute-phase reactants and Janus kinase (JAK)"

Abstract Number: 523 • 2019 ACR/ARP Annual Meeting
The Impact of Upadacitinib versus Methotrexate or Adalimumab on Individual and Composite Disease Measures in Patients with Rheumatoid Arthritis
Ronald van Vollenhoven¹, Andrew Östör ², Eduardo Mysler ³, Nemanja Damjanov ⁴, In-Ho Song ⁵, Yanna Song ⁶, Jessica Suboticki ⁵ and Vibeke Strand ⁷, ¹Amsterdam Rheumatology and Immunology Center ARC, Amsterdam, the Netherlands, Amsterdam, Netherlands, ²Cabrini Medical Centre, Monash University, Malvern, Australia, Malvern, Australia, ³Organización Medica de Investigación, Buenos Aires, Argentina, Buenos Aires, Argentina, ⁴Institute of Rheumatology, Belgrade University School of Medicine, Belgrade, Serbia, Belgrade, Serbia, ⁵AbbVie Inc., North Chicago, IL, USA, North Chicago, IL, ⁶AbbVie Inc., North Chicago, IL, USA, North Chicago, ⁷Division of Immunology/Rheumatology, Stanford University, Stanford, CA
Background/Purpose: In Phase 3 trials, upadacitinib (UPA), an oral JAK1-selective inhibitor, has been assessed as monotherapy vs MTX (SELECT-EARLY1) and in combination with MTX vs…